[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369526-105":59,"doc-detail-369526-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","genomic-landscape-and-homologous-recombination-repair-deficiency-signature-in-stage-i-iii-and-de-novo-stage-iv-primary-breast-cancers","Genomic landscape and homologous recombination repair deficiency signature in stage I-III and de novo stage IV primary breast cancers","","Purpose: Compare genomic alterations and a homologous recombination deficiency (HRD) signature (HRDsig) between primary tumors from stage I-III and de novo stage IV, and between stage I-III cases with early (\u003C2 years) versus late (>2 years) recurrence. Methods: Analyze de-identified genomic and clinical data for stage I-III (N=910) and stage IV (N=783) breast cancers from the Flatiron Health/Foundation Medicine nationwide clinico-genomic database. Results: No significant stage differences in genomic alteration frequencies; most prevalent biomarkers include PIK3CA mutation and HRDsig positivity. Conclusions: HRDsig reveals ~16% of tumors without g/sBRCA or gPALB2 alterations that may benefit from PARP inhibitors or platinum-based therapy, warranting future clinical validation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/genomic-landscape-and-homologous-recombination-repair-deficiency-signature-in-stage-i-iii-and-de-novo-stage-iv-primary-breast-cancers/369526/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/genomic-landscape-and-homologous-recombination-repair-deficiency-signature-in-stage-i-iii-and-de-novo-stage-iv-primary-breast-cancers/369526.png","ImageObject",300,407,{"name":92,"@type":93},"Jordan Avery","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of comparing stage I-III with de novo stage IV breast cancers?","Question",{"text":112,"@type":113},"The study compared genomic alterations and an HRD signature (HRDsig) between primary tumors from stage I-III and those from de novo stage IV, and also contrasted early versus late recurrence within stage I-III.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were genomic alterations and HRDsig measured in the study?",{"text":117,"@type":113},"De-identified genomic and clinical data were analyzed, including mutation status of 324 cancer-related genes and HRDsig, a DNA scar-based measure of homologous recombination deficiency.",{"name":119,"@type":110,"acceptedAnswer":120},"What does HRDsig show in breast cancers without g/sBRCA or gPALB2 alterations?",{"text":121,"@type":113},"HRDsig positivity was identified in about 16% of such cancers, suggesting potential benefit from PARP inhibitors or platinum-based treatments and the need for future clinical testing.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369526,1790536132,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":44,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},1099523882367,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Genomic landscape and homologous recombination repair deficiency signature in stage I-III and de novo stage IV primary breast cancers  \nJune E. Jeon1,, Kuei-Ting Chen2, Russell Madison2,, Alexa B. Schrock2, Ethan Sokol2,, MiaA. Levy2,, Mariya Rozenblit3,, Richard S. P. Huang2, Lajos Pusztai*,3,  \n1Department of Internal Medicine, Greenwich Hospital, Greenwich, CT, USA 2Foundation Medicine, Cambridge, MA, USA  \n3Yale Cancer Center, Yale School of Medicine, New Haven, CT, USA  \n*Corresponding author: Lajos Pusztai, MD, DPhil, Yale Cancer Center, 35 Park Street, New Haven, CT 06511, USA ([lajos.pusztai@yale.edu](lajos.pusztai@yale.edu)) .  \nAbstract  \nPurpose: We compared genomic alterations and a homologous recombination deficiency (HRD) signature (HRDsig) in primary tumors from stage I-III to those in de novo stage IV breast cancers and from stage I-III cancers with early (\u003C2 years after diagnosis) versus late (>2 years) recurrence.  \nMethods: De-identified genomic and clinical data of primary breast cancers (stage I-III N = 910, stage IV N = 783) from the United States, the nationwide clinico-genomic database of Flatiron Health and Foundation Medicine were analyzed. Genomic results included the mutation status of 324 cancer-related genes and HRDsig, a DNA scar-based measure of HRD.  \nResults: No significant differences were observed in the frequencies of genomic alterations across disease stages, or between stage I-III cancers with early versus late relapse. Overall, the most prevalent biomarkers were PIK3CA mutation and HRDsig positivity. HRDsig positivity was observed in 82% of germline or somatic g/sBRCA1/2 or germline PALB2 (gPALB2) mutated cancers, 13. 1% in cancers with other HR-repair (HRR) gene alterations (ATM, BARD1, BRIP1, CDK12, CHEK1, CHEK2, FANCL, somatic PALB2 (sPALB2), RAD51B, RAD51C, RAD51D and RAD54L), and also in 16. 5% of HRR wild-type cancers. HRDsig positivity was observed across receptor subtypes and was the highest inTNBC (30%), followed by ER+/HER2-cancers (17%), then HER2 + cancers (8 .7%) .  \nConclusions: Early-stage (I-III) and de novo stage IV breast cancers shared a similar prevalence of targetable genomic alterations and overall genomic landscape. HRDsig identified approximately 16% of breast cancers without g/sBRCA/gPALB2 alteration that might potentially benefit from PARP inhibitors or platinum-based treatments and should be tested in future clinical studies.  \nKey words: genomic; breast cancer; recurrence; homologous recombination repair; targeted molecular therapy; homologous recombination deficiency signature.  \nImplications for Practice  \nComprehensive genomic profiling data from cancer biopsies is used to guide treatment. Our study shows that primary tumors of stage I-III and stage IV breast cancers share similar targetable genetic alterations and similar overall genomic landscapes. We also found that a novel DNA scar-based biomarker of homologous recombination deficiency (HRDsig) is observed in 16% of breast cancers without g/ sBRCA/gPALB2 alteration, that raise the possibility of benefit from PARP inhibitors or platinum-based treatment. Future clinical trials are needed to validate the predictive value of HRDsig.  \nIntroduction  \nOver 300 000 new cases of breast cancer will be diagnosed in the United States in 2025 and more than 90% of newly diagnosed breast cancers are stage I-III disease; the rest are stage IV cancers, also called de novo metastatic breast cancer.1 Systemic therapies administered before and/or after surgery for stage I-III cancers are increasingly effective in eradicating micrometastatic disease. Consequently, metastatic recurrences of stage I-III breast cancers are steadily decreasing while the proportion of de novo stage IV cancers among metastatic  \nbreast cancers is increasing. Historically, about 20% of metastatic breast cancers were stage IV disease and the rest were recurrences; the contemporary proportion of stage IV cancers among all metastatic cancers is clos","cbCaibPx8CMMt8wo","https://ap.wps.com/l/cbCaibPx8CMMt8wo","pdf",1117461,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusions\n## Implications for Practice\n# Introduction","[{\"question\":\"What was the purpose of comparing stage I-III with de novo stage IV breast cancers?\",\"answer\":\"The study compared genomic alterations and an HRD signature (HRDsig) between primary tumors from stage I-III and those from de novo stage IV, and also contrasted early versus late recurrence within stage I-III.\"},{\"question\":\"How were genomic alterations and HRDsig measured in the study?\",\"answer\":\"De-identified genomic and clinical data were analyzed, including mutation status of 324 cancer-related genes and HRDsig, a DNA scar-based measure of homologous recombination deficiency.\"},{\"question\":\"What does HRDsig show in breast cancers without g/sBRCA or gPALB2 alterations?\",\"answer\":\"HRDsig positivity was identified in about 16% of such cancers, suggesting potential benefit from PARP inhibitors or platinum-based treatments and the need for future clinical testing.\"}]","Genomic landscape and homologous recombination repair deficiency signature in stage I-III and de novo stage IV primary breast cancers | PDF",1790183242,23,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/79b40ffb2914c902face8742bee569c6.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7a88e11f94739e34dcabe4e4bb5e38a6.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d9f60fe7eb28adfa3e94228e384e8721.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7cb8333939be646c94bbe4ef5169cd52.webp",980,1287]